Overview

Somatuline Predictive Factors in Acromegaly and NET

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
Details
Lead Sponsor:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin